The stock of Edwards Lifesciences Corp (EW) has seen a -1.58% decrease in the past week, with a -5.60% drop in the past month, and a 2.19% flourish in the past quarter. The volatility ratio for the week is 2.16%, and the volatility levels for the past 30 days are at 2.14% for EW. The simple moving average for the past 20 days is -4.28% for EW’s stock, with a -8.48% simple moving average for the past 200 days.
Is It Worth Investing in Edwards Lifesciences Corp (NYSE: EW) Right Now?
The price-to-earnings ratio for Edwards Lifesciences Corp (NYSE: EW) is 10.09x, which is above its average ratio. Moreover, the 36-month beta value for EW is 1.11. Analysts have varying opinions on the stock, with 9 analysts rating it as a “buy,” 5 as “overweight,” 19 as “hold,” and 1 as “sell.”
The public float for EW is 579.26M and currently, short sellers hold a 1.95% of that float. On January 22, 2025, EW’s average trading volume was 5.02M shares.
EW) stock’s latest price update
Edwards Lifesciences Corp (NYSE: EW)’s stock price has soared by 0.27 in relation to previous closing price of 69.78. Nevertheless, the company has seen a loss of -1.58% in its stock price over the last five trading days. zacks.com reported 2025-01-16 that EW stock is on investors’ radar courtesy to the promising structural heart opportunities post the divestment of the Critical Care arm.
Analysts’ Opinion of EW
Many brokerage firms have already submitted their reports for EW stocks, with Wolfe Research repeating the rating for EW by listing it as a “Underperform.” The predicted price for EW in the upcoming period, according to Wolfe Research is $60 based on the research report published on January 16, 2025 of the current year 2025.
Morgan Stanley gave a rating of “Equal-Weight” to EW, setting the target price at $70 in the report published on October 11th of the previous year.
EW Trading at -2.13% from the 50-Day Moving Average
After a stumble in the market that brought EW to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -27.21% of loss for the given period.
Volatility was left at 2.14%, however, over the last 30 days, the volatility rate increased by 2.16%, as shares sank -3.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +4.92% upper at present.
During the last 5 trading sessions, EW fell by -1.58%, which changed the moving average for the period of 200-days by -24.78% in comparison to the 20-day moving average, which settled at $73.10. In addition, Edwards Lifesciences Corp saw -5.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EW starting from Lippis Daniel J., who sale 500 shares at the price of $68.76 back on Jan 16 ’25. After this action, Lippis Daniel J. now owns 23,189 shares of Edwards Lifesciences Corp, valued at $34,382 using the latest closing price.
BOBO DONALD E JR, the CVP,Strategy/Corp Development of Edwards Lifesciences Corp, sale 5,000 shares at $68.75 during a trade that took place back on Jan 16 ’25, which means that BOBO DONALD E JR is holding 46,936 shares at $343,736 based on the most recent closing price.
Stock Fundamentals for EW
Current profitability levels for the company are sitting at:
- 0.27 for the present operating margin
- 0.78 for the gross margin
The net margin for Edwards Lifesciences Corp stands at 0.71. The total capital return value is set at 0.14. Equity return is now at value 17.93, with 13.01 for asset returns.
Based on Edwards Lifesciences Corp (EW), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at 1.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 57.44.
Currently, EBITDA for the company is 1.77 billion with net debt to EBITDA at -1.74. When we switch over and look at the enterprise to sales, we see a ratio of 6.52. The receivables turnover for the company is 7.24for trailing twelve months and the total asset turnover is 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.46.
Conclusion
To wrap up, the performance of Edwards Lifesciences Corp (EW) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
